Sales up 24%, EBIT down 29% Sales, EBIT 6% and 26% lower than our expectations Guidance maintained ...
Redeye positively views the news that Lifeclean has developed an effective method for removing PFAS ...
Smart High Tech publicerade den 8 november 2022 bolagets delårsrapport för tredje kvartalet 2022.
Redeye continues to see a very compelling ling term investment case.
Redeye states Gasporox report was strong with beats accross the board.
EBIT missed ABGSCe by 80%, mainly on softer sales Expect cons to cut ‘22e EBIT by 27% There is a con...
Sales & adj. EBIT above our expectations We cut adj.
Sales and EBIT beat of 45% and 17% We raise estimates on Q3 numbers and eMELT Positive outlook intac...
Solid customer intake but sequential margin contraction We cut ‘22e-‘24e EBITDA by 3-6% 12x-11x ‘22e...
Relais reported Q2 adjusted EBITA of EUR 7.9m, 4% below our estimate.
Raketech just released a decent Q3 report, and a start of the fourth quarter in-line with our foreca...
Redeye provides its initial take on Surgical Science’s Q3 2022 report, which came in above our estim...
Redeye strengthens its positive view on Vertiseit following a solid Q3, showing significant margin i...
Redeye updates on Better Collective ahead of its Q3-results (due 17 November) where we expect solid ...
Redeye is surprised by Vitec announcing a directed share issue.
Cibus's Q3 2022 income from property management (IFPM) was above consensus when adjusted for EUR -1.
Redeye decreases its fair value range for aXichem after reviewing the case and making significant ch...
Redeye is encouraged by the strong Q3 numbers including group sales hitting a new ATH.
RU equipment sales to fall off, aftermarket stronger SEK 321m VCE payment added as a one-off We expe...
Sales and EBIT loss +45% and -17% vs. ABGSCe Lower costs than expected, worse cash flow due to WC Sh...
